Multiple Sclerosis: LIFNano-CD4 for Trojan Horse Delivery of the Neuro-Protective Biologic “LIF” Into the Brain: Preclinical Proof of Concept
Authors:
Open Access
- 7 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medical Technology
- Vol. 3, 640569
Abstract
Multiple sclerosis (MS) is a demyelinating autoimmune disease that attacks the brain, with year-on-year loss of brain volume, starting late teens and becoming manifest late twenties. There is no cure, and current therapies are immunosuppressive only. LIF is a vital stem cell growth factor active throughout life—and essential for health of the central nervous system (CNS), being tolerogenic, myelinogenic, and neuroprotective. Nano-formulation of LIF (LIFNano) using FDA-approved PLGA captures LIF's compound therapeutic properties, increasing potency 1,000-fold when targeted to CD4 (LIFNano-CD4). Moreover, circulating CD4+ lymphocytes are themselves regulated by LIF to express the Treg phenotype, known to release T cell-derived LIF upon engagement with cognate antigen, perpetuating antigen-specific self-tolerance. With the longer-term aim of treating inflammatory lesions of MS, we asked, does LIFNano-CD4 cross the blood–brain barrier (BBB)? We measure pK and pD using novel methodologies, demonstrate crossing of the BBB, show LIF-cargo-specific anti-inflammatory efficacy in the frontal cortex of the brain, and show safety of intravenous delivery of LIFNano-CD4 at doses known to provide efficacious concentrations of LIF cargo behind the BBB.Keywords
Funding Information
- Innovate UK
This publication has 17 references indexed in Scilit:
- T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunityNature Communications, 2017
- Pharmacokinetics and Biodistribution of the Illegal Food Colorant Rhodamine B in RatsJournal of Agricultural and Food Chemistry, 2017
- Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)Biomaterials, 2015
- Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouseMultiple Sclerosis and Related Disorders, 2012
- Cytokine Signaling Modulates Blood-Brain Barrier FunctionCurrent Pharmaceutical Design, 2011
- LIF in the regulation of T-cell fate and as a potential therapeuticGenes & Immunity, 2011
- Modulation of CD4+ T Lymphocyte Lineage Outcomes with Targeted, Nanoparticle-Mediated Cytokine DeliveryMolecular Pharmaceutics, 2010
- Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6Cell Cycle, 2009
- Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammationNature Medicine, 2007
- Toxicity and Tissue Distribution of Magnetic Nanoparticles in MiceToxicological Sciences, 2005